Merck and Moderna maintain a targeted licensing and co-development partnership on their mRNA-4157/Keytruda cancer vaccine, with recent Phase 3 melanoma success and commercialization preparations via expanded Tempus collaboration reinforcing this structure rather than prompting full integration. Merck's ongoing $550 million facility investments and Moderna's convertible notes issuance underscore independent capital strategies and oncology pipelines, aligning with historical precedent where large pharma-biotech deals favor licensing over mergers. With roughly ten weeks remaining in 2026 and no regulatory or earnings catalysts signaling strategic shifts, trader consensus prices negligible probability of an announced transaction. Tail risks remain limited to unforeseen board-level pivots if vaccine launch economics deteriorate sharply.